Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Virax Biolabs Group's Total Liabilities for the quarter that ended in Mar. 2026 was $0.99 Mil. Virax Biolabs Group's Total Assets for the quarter that ended in Mar. 2026 was $8.32 Mil.
Therefore, Virax Biolabs Group's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.12.
Virax Biolabs Group (NAS:VRAX) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Virax Biolabs Group Liabilities-to-Assets Related Terms
Virax Biolabs Group Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRAX vs RNAZ, OGEN, ONCO: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Virax Biolabs Group's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Liabilities-to-Assets falls into.
Virax Biolabs Group Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Virax Biolabs Group's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Liabilities-to-Assets of 0.12 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Liabilities-to-Assets too high?
Virax Biolabs Group's current Liabilities-to-Assets is 0.12. Overall, Virax Biolabs Group has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Liabilities-to-Assets compare to RNAZ and OGEN?
Virax Biolabs Group's Liabilities-to-Assets of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current Liabilities-to-Assets is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.53, compared to a current price of $2.59 — trading 26.6% below its estimated fair value. The current Liabilities-to-Assets is 0.12. Virax Biolabs Group's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Liabilities-to-Assets is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $2.59 is trading 26.6% below its estimated GF Value™ of $3.53.
GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.
Key valuation signals for VRAX:
Liabilities-to-Assets: 0.12
GF Value™: $3.53 vs. price of $2.59 (26.6% below fair value)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
44GF Score
Get the complete analysis for VRAX
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
